hLAG3/hPD-1(BALB/c)
Nomenclature
BALB/cJSmo-Pdcd1tm1(hPDCD1)Lag3tm1(hLAG3)Smoc
Cat. NO.
NM-XA-242014
Strain State
Repository Live
Model Description
Validation Data
Fig.1 Detection of PD-1 expression on CD4+ T cells and Tregs in spleen of hLAG3/hPD-1(BALB/cSmoc) mice by FACS. Mice were administred Con A (12.5 mg/kg) by intravenous injection. At 18 h post injection, spleen was collected from the wild-type mouse (male, 7 weeks old) and homozygous hLAG3/hPD-1(BALB/cSmoc) mice (male, 7 weeks old), and analyzed by flow cytometry with anti-mPD-1 and anti-hPD-1.
Abbr. HO, homozygous; WT, wild type.
Fig.2 Detection of LAG3 expression on T cells in spleen of WT BALB/c mice and HO hPD-1/hLAG3(BALB/cSmoc) mice by FACS. Mice were administred Con A (12.5 mg/kg) by intravenous injection. At 18 h post injection, splenocytes were collected from the wild-type mouse (male, 11 weeks old) and homozygous hPD-1/hLAG3(BALB/cSmoc) mice (male, 11 weeks old), and analyzed by flow cytometry with anti-mLAG3 and anti-hLAG3. Human LAG3 was exclusively detectable on T cells from hPD-1/hLAG3(BALB/cSmoc) mice but not on those cells from WT mice. In contrast, mouse LAG3 was exclusively detectable on WT mice but not in hPD-1/hLAG3(BALB/cSmoc) mice.
Abbr. HO, homozygous; WT, wild type.
Fig.3 Detection of LAG3 expression on CD4+T cells in spleen of WT BALB/c mice and HO hPD-1/hLAG3(BALB/cSmoc) mice by FACS. Mice were administred Con A (12.5 mg/kg) by intravenous injection. At 18 h post injection, splenocytes were collected from the wild-type mouse (male, 11 weeks old) and homozygous hPD-1/hLAG3(BALB/cSmoc) mice (male, 11 weeks old), and analyzed by flow cytometry with anti-mLAG3 and anti-hLAG3. Human LAG3 was exclusively detectable on CD4+ and CD8+ T cells from hPD-1/hLAG3(BALB/cSmoc) mice but not on those cells from WT mice. In contrast, mouse LAG3 was exclusively detectable on WT mice but not in hPD-1/hLAG3(BALB/cSmoc) mice.
Abbr. HO, homozygous; WT, wild type.
Fig.4 In vivo efficacy of Relatlimab plus Nivolumab in hLAG3/hPD-1(BALB/cSmoc) mice. Means of tumor volume(A) and body weight(B). Female, 10-13-week-old homozygous hLAG3/hPD-1(BALB/cSmoc) mice were inoculated subcutaneously in the right flank with CT26 tumor cells (1×106 cells) and grouped when the mean tumor size reaches approximately 100 mm3. Mice received PBS (Group 1), Nivolumab (Group 2, 1 mg/kg) and Relatlimab plus Nivolumab (Group 3, 10 mg/kg Relatlimab and 1 mg/kg Nivolumab) intraperitoneal injection. The tumor volume and body weight were measured twice a week.(n=6, Mean±SEM, t-test, * p < 0.05, ns, no significance).
Table 1. Blood routine examination of HO hLAG3/hPD-1(BALB/c) mice. The baseline physiological parameters of HO hLAG3/hPD-1(BALB/c) mice showed no significant abnormalities.Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SD.
Table 2. Biochemical test of serum from HO hLAG3/hPD-1(BALB/c) mice. Abbr. HO, homozygous; WT, wild type. Values are expressed as mean±SD.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn moreMilestones
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
Learn more
